Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Angeforderte Firma
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions Weiterlesen
I have only been with Karyopharm for less than 3 months, but I am very happy with my decision to join the team!
Was ist am positivsten an Kultur und Umgang in Ihrem Unternehmen?
The excitement associated with the expanded use of XPOVIO.
Was macht Sie bei der Arbeit am glücklichsten?
Meeting the needs of the teams that I support. Trying to help them be more efficient.
Other Employee Reviews for Karyopharm Therapeutics
×